Ontology highlight
ABSTRACT: Background
DNA vaccines remain an important component of HIV vaccination strategies, typically as part of a prime/boost vaccination strategy with viral vector or protein boost. A number of DNA prime/viral vector boost vaccines are currently being evaluated for both preclinical studies and in Phase I and Phase II clinical trials. These vaccines would benefit from molecular adjuvants that increase correlates of immunity during the DNA prime. While HIV vaccine immune correlates are still not well defined, there are a number of immune assays that have been shown to correlate with protection from viral challenge including CD8+ T cell avidity, antigen-specific proliferation, and polyfunctional cytokine secretion.Methodology and principal findings
Recombinant DNA vaccine adjuvants
SUBMITTER: Kanagavelu SK
PROVIDER: S-EPMC3253891 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature